Kitchener, Canada
Rapid Novor, founded in 2015 as a University of Waterloo spin-off, is at the forefront of antibody protein sequencing technology, specifically within the sectors of Biotechnology and Health Care. Headquartered in Canada, the company leverages over twenty years of scientific innovation from co-founder and chief scientist, Dr. Bin Ma.
The core technology developed by Rapid Novor Inc. capitalizes on mass spectrometry-based proteomics, allowing for the direct sequencing of antibody proteins without the need for the producing cell line. Their flagship service, REmAb®, routinely delivers precise antibody sequences, while their WILD™ service uniquely distinguishes between isobaric Isoleucine and Leucine using mass spectrometry.
Despite no recent investment, Rapid Novor remains critical for advancing life sciences and enhancing human health through next-generation sequencing. Their innovative approach positions them as a leader capable of attracting future investors seeking cutting-edge biotech ventures.
Y-Biologics
